We refer readers to Table H in the Appendix to the CY 2017 Quality Payment Program final rule (81 FR 77177 through 77199), Tables F and G in the Appendix to the CY 2018 Quality Payment Program final rule (82 FR 54175 through 54229), Tables A and B in the Appendix 2 to the CY 2019 PFS final rule (83 FR 60286 through 60303), Tables A, B, and C in the Appendix 2 to the CY 2020 PFS final rule (84 FR 63514 through 63538), Tables A, B, and C in the Appendix 2 to the CY 2021 PFS final rule (85 FR 85370 through 85377), Tables A, B, and C in the Appendix 2 to the CY 2022 PFS final rule (86 FR 65969 through 65997), Tables A, B, and C in the Appendix 2 to the CY 2023 PFS final rule (70633 through 70650), and Tables A, B, and C in the Appendix 2 to the CY 2024 PFS final rule (88 FR 79965 through 79977) for our previously finalized improvement activities Inventories
We note that since the data indicating which drugs will have an increased applicable percentage of 26 percent for the unique circumstances of rarely utilized orphan drugs ( 414.940(d)(5)) will not be available until the data is analyzed for the initial report, we entered 26 percent for orphan drugs furnished to fewer than 100 beneficiaries in CY 2022 based on data on the CMS website
(9) Similar to how other Innovation Center models may test new measures during their implementation (for example, the Comprehensive Joint Replacement model (80 FR 73358 through 73382 and 86 FR 23543 through 23549) and the Guiding an Improved Dementia Experience (GUIDE) Model [612] ), what role could an ambulatory specialty model have in testing potential new measures, such as relevant PRO-PMs, by gathering data for consideration in future MVP measure sets
As required under section 1847A(i)(3)(G)(i) of the Act, CMS will reduce the total rebate amount calculated under 427.301(a), if any is owed, for a Part B rebatable drug that is currently in shortage, as defined in 427.400, at any point during the applicable calendar quarter
